Compare FSP & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | NSRX |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 37.1M |
| IPO Year | 2001 | 2024 |
| Metric | FSP | NSRX |
|---|---|---|
| Price | $0.41 | $3.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 1.2M | 16.3K |
| Earning Date | 10-27-2026 | 08-17-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $16.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.98 |
| 52 Week High | $1.28 | $9.50 |
| Indicator | FSP | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 40.21 |
| Support Level | $0.42 | $2.98 |
| Resistance Level | $0.51 | $3.61 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 59.51 | 18.33 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.